The Utility of Iron Chelators in the Management of Inflammatory Disorders
Open accessThe DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index; 20 of the 88 sources its claims cite were checked for support.
Abstract
Since iron can contribute to detrimental radical generating processes through the Fenton and Haber‐Weiss reactions, it seems to be a reasonable approach to modulate iron‐related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.
Overview
CoChat Summary
TL;DR
This review argues that iron-catalyzed reactive oxygen species contribute to acute and chronic inflammatory diseases, and that iron chelators may offer therapeutic benefit by sequestering redox-active iron. It surveys experimental and clinical evidence across cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia, and iron overload/deficiency contexts, while noting risks and the need for better chelators.
Key findings
- Iron is essential but can catalyze ROS via Fenton and Haber-Weiss reactions; dysregulated iron homeostasis is linked to progressive inflammatory/degenerative diseases and cancer. The body contains approximately 3–4 g iron: hemoglobin accounts for 65%, ferritin/hemosiderin 25%, myoglobin/cytochromes/other enzymes 10%, and transferrin-bound iron about 0.1%; absorption is around 1 mg/day in men and 2 mg/day in women, and macrophage iron recycling is 20-fold greater than daily intestinal absorption.
- Inflammation triggers hypoferremia/anemia of inflammation through cytokines such as IL-6 and hepcidin; hepcidin binds ferroportin, causing its internalization and degradation, trapping iron in macrophages and hepatocytes and inhibiting intestinal iron absorption.
- Chelation studies report benefits in models: deferoxamine reduced adiposity via oxidative stress and inflammation in obese/type 2 diabetes KKAy mice, with only mild but not significant reductions in hemoglobin and hematocrit after two weeks; in UUO mice, deferoxamine reduced fibrotic progression, interstitial macrophage infiltration, IL-1β and MCP-1 expression, and myofibroblast accumulation; in pigs, deferoxamine attenuated lipid peroxidation, inhibited IL-6, and diminished SIRS and MOD; in rat colitis, highest-dose maltol was comparable to prednisolone and to deferoxamine/deferiprone.
- Clinical/contextual evidence notes that iron overload in hemochromatosis and thalassemia increases susceptibility to infections; the Pemba trial led to adverse events in children receiving iron in a malaria-endemic region; and in tuberculosis, iron supplementation increased mycobacterial growth and morbidity/mortality. New chelators designed to hold iron in a non-redox-active state may improve efficacy, whereas conventional chelators can be utilized by pathogens as iron sources.
Methods
- Narrative review whose objective was to highlight mechanisms of iron regulation and iron chelation and to demonstrate the potential impact of this strategy in several acute and chronic inflammatory diseases, including cancer.
- Data source: literature regarding experimental and clinical evidence for iron-related anti-inflammatory strategies; no primary patient cohort or systematic search strategy is described.
- Main analysis: qualitative synthesis of mechanistic pathways and disease-specific studies covering cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia of inflammation, hereditary/acquired iron overload, and iron deficiency.
Limitations
- Stated: iron depletion as therapy is controversial because stored iron is often assumed to be inherently safe; the benefit of iron depletion can only be rigorously demonstrated in relation to iron in excess of needs; appropriate trials to rule out potential hazards of iron stores have not been undertaken; short-term harm such as anemia is possible; and conventional chelators may promote infection or be utilized by pathogens.
- Evident: as a narrative review, there is no systematic search, risk-of-bias assessment, or meta-analysis, and many experimental findings come from animal models while clinical evidence remains limited or observational.
- Evident: no primary data or sample size are reported, so efficacy conclusions are synthesized from heterogeneous studies rather than tested in a single controlled trial.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
13 Valid · 4 Not valid · 49 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Importantly, dysregulated iron homeostasis is associated with progressive inflammatory and degenerative diseases, as well as cancer [2].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 1. Introduction
What the sources say
- Supportedcites [2] Kell D. B. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Medical Genomics 2009 2, article 2 10.1186/1755-8794-2-2 2-s2.0-65449120792 PMC2672098 19133145 source
The Abstract > Review passage states the paper reviews 'the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance', covering cardiovascular, metabolic and neurological diseases and aging — i.e. progressive inflammatory and degenerative diseases. Section-level passages reinforce deranged iron metabolism in specific disorders (e.g. Psoriasis: 'clear evidence for the involvement of a deranged iron metabolism'; Diabetes: 'Serum ferritin and body iron stores are strongly associated with diabetes'; Neurodegeneration: 'Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases'). A dedicated 'Cancer and oncology' section links iron to oncogenesis (mutagenic Fenton chemistry, NGAL overexpression in tumours, iron restriction limiting tumour growth), so the cancer extension is also covered. The claim's hedged 'is associated with' is weaker than the paper's aetiological framing, which is acceptable. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Proinflammatory cytokines induced by inflammation can stimulate anemia of inflammation by limiting serum iron and increasing cellular iron stores by modulating the expression and activity of various iron regulatory proteins including hepcidin, FPN, ferritin, and the iron importer divalent metal transporter 1 (DMT1) [25–30].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 2. Basic Mechanisms > 2.2. Iron and ROS
What the sources say
- Partly supportedcites [25] Nemeth E. Rivera S. Gabayan V. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin Journal of Clinical Investigation 2004 113 9 1271 1276 10.1172/JCI200420945 2-s2.0-2342510407 15124018 PMC398432 sourceExperimental — accuracy not yet measured
Our copy supports the core of the claim: the Abstract and Discussion state that IL-6 is 'the necessary and sufficient cytokine for the induction of hepcidin during inflammation' and that the IL-6-hepcidin axis causes the hypoferremia (limited serum iron) of anemia of inflammation, with the Introduction noting hepcidin inhibits release of recycled iron from macrophages and intestinal iron absorption (i.e., iron sequestration into cells). However, the paper does not support modulation of FPN (ferroportin) or DMT1 by proinflammatory cytokines — ferroportin/Ireg1 and DMT1 appear only in the titles of cited works in the References (refs 26, 29), and ferritin is mentioned only descriptively in the Introduction ('normal to elevated ferritin concentrations') as a feature of AI credited to ref 17, not as a cytokine-regulated target. So the hepcidin/serum-iron part is confirmed while the FPN, ferritin and DMT1 elements of the enumerated protein list are not attributable to this source. (LLM, conf=0.80)
- Partly supportedcites [26] Wrighting D. M. Andrews N. C. Interleukin-6 induces hepcidin expression through STAT3 Blood 2006 108 9 3204 3209 10.1182/blood-2006-06-027631 2-s2.0-33751175421 16835372 PMC1895528 sourceExperimental — accuracy not yet measured
Our copy supports the cytokine→hepcidin→low-serum-iron core of the sentence: the Introduction states hepcidin 'is a circulating hormone that is induced by inflammation, which blocks the release of iron from macrophages and interrupts intestinal iron absorption,' and that 'Administration of IL-6 to human subjects stimulates increased hepcidin production and results in low serum iron (hypoferremia) in vivo,' with the Abstract/Results establishing IL-6→STAT3 as the mechanism (this paper's own contribution). What this source does not support is the rest of the attribution: it never addresses modulation of ferroportin, ferritin, or DMT1 expression/activity (ferroportin appears only inside the title of a cited reference, Nemeth et al. 2004, ref. 2), nor does it report an increase in cellular iron stores. Searches for 'ferroportin/ferritin/divalent metal transporter 1' and for 'cellular iron stores/hypoferremia' returned no substantive passage. (LLM, conf=0.75)
- Partly supportedcites [27] Wang J. Song N. Jiang H. Xie J. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons Biochimica et Biophysica Acta—Molecular Basis of Disease 2013 1832 5 618 625 10.1016/j.bbadis.2013.01.021 2-s2.0-84874436258 23376588 sourceExperimental — accuracy not yet measured
Our copy supports the cellular-mechanism core: Section 3.1/3.2 and the Discussion (Figs. 1-2) show IL-1² or TNF-α upregulate DMT1+IRE and TfR1, downregulate FPN1 via IRP1, increase hepcidin mRNA (2.69- and 3.32-fold), and raise intracellular iron in ventral mesencephalic neurons. But the paper is an in vitro/MPTP mouse neuroscience study: no passage addresses anemia of inflammation, limiting serum iron, or ferritin modulation (ferritin appears only in the titles of cited refs 17 and 39), so those parts of the claim are not supported by this source. The hepcidin-STAT3 and FPN-internalization points in Section 3.2 are themselves credited to refs 27 and 28, though the paper reports its own hepcidin mRNA data. (LLM, conf=0.78)
- Partly supportedcites [28] Urrutia P. Aguirre P. Esparza A. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells Journal of Neurochemistry 2013 126 4 541 549 10.1111/jnc.12244 2-s2.0-84885953717 23506423 sourceExperimental — accuracy not yet measured
Urrutia et al. (2013) supports the cellular-arm of the claim: inflammatory stimuli (TNF-a, IL-6, LPS) increase DMT1 expression in neurons, astrocytes and microglia, induce hepcidin in astrocytes and microglia, and hepcidin decreases FPN1, with the net result of iron accumulation in neurons and microglia (Abstract; Discussion; Fig. 6 legend). However, our copy is a rat CNS cell study and contains nothing about anemia of inflammation or the systemic restriction of serum iron — it only refers to 'previous reports indicating that inflammatory stimuli induce the systemic synthesis of the master iron regulator hepcidin'. Ferritin is likewise not a finding here: it appears only as background ('the iron storage protein ferritin') and as another group's result (Hunter et al. 2008, increased ferritin expression after striatal LPS). The claim's 'and activity' extension is also unsupported — the paper measures expression/abundance and even notes that astrocytic iron efflux did not change despite decreased FPN1 (Rathore et al. 2012), and astrocytes showed no iron accumulation. (LLM, conf=0.78)
- Partly supportedcites [29] Rivera S. Liu L. Nemeth E. Gabayan V. Sorensen O. E. Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia Blood 2005 105 4 1797 1802 10.1182/blood-2004-08-3375 2-s2.0-13544252463 15479721 sourceExperimental — accuracy not yet measured
Our copy supports the hepcidin component of the claim: the Introduction states that inflammatory stimuli and IL-6 raise hepcidin, leading to hypoferremia and iron-refractory anemia, and the Chronic effects/Discussion show hepcidin lowering serum iron while sequestering iron in hepatocytes (Abstract; Chronic effects of hepcidin, p. 'It is often stated but not convincingly documented...'). However, the claim also attributes modulation of ferroportin (FPN), ferritin and DMT1 to this source, and no passage of our copy mentions any of those three proteins — searches for 'ferroportin', 'ferritin', 'divalent metal transporter 1/DMT1' returned only unrelated passages and reference-list entries. The unsupported part of the multi-citation sentence (25-30) is the FPN/ferritin/DMT1 modulation. (LLM, conf=0.78)
- Partly supportedcites [30] Atkinson S. H. Rockett K. A. Morgan G. Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia inWest African children Blood 2008 112 10 4276 4283 10.1182/blood-2008-06-162008 2-s2.0-61849125779 18716131 PMC2581977 sourceExperimental — accuracy not yet measured
Our copy supports much of the mechanism: the Introduction states TNF-alpha induces hypoferremia by inhibiting iron release from macrophage storage compartments and by transcriptional induction of ferritin, and the Discussion adds that TNF-alpha blocks intestinal iron absorption via enterocyte ferritin deposition and relocalization of ferroportin from the basolateral membrane. However, DMT1 is never mentioned anywhere in our copy (searched: DMT1, divalent metal transporter, ferroportin/hepcidin), and hepcidin appears only as a mechanism TNF-alpha acts INDEPENDENTLY of, not as a cytokine-modulated iron regulator; the paper's own data also concern iron deficiency/IDA in malaria-exposed Gambian children rather than anemia of inflammation. So the hepcidin and DMT1 elements of the attributed list, and the anemia-of-inflammation framing, are not supported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Oxidative stress may also modulate signal transduction pathways associated with malignancy [53].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.1. Cancer
What the sources say
- Supportedcites [53] Benhar M. Engelberg D. Levitzki A. ROS, stress-activated kinases and stress signaling in cancer EMBO Reports 2002 3 5 420 425 10.1093/embo-reports/kvf094 2-s2.0-0035984912 11991946 PMC1084107 source
The “ROS and cancer” section says ROS regulate cellular signaling, are elevated in cancer cells, and can affect transcription-factor and receptor-tyrosine-kinase signaling during tumor progression. This supports the hedged claim that oxidative stress may modulate malignancy-associated signaling pathways; page numbers were not supplied. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.4. Renal Fibrosis
What the sources say
- Supportedcites [67] Ikeda Y. Ozono I. Tajima S. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction PLoS ONE 2014 9 2 e89355 10.1371/journal.pone.0089355 2-s2.0-84897786390 PMC3929716 24586712 source
The Discussion (opening paragraph) states that in UUO mice DFO suppressed renal interstitial fibrosis and collagen I/III/IV expression, prevented macrophage infiltration and inflammatory cytokine induction, and diminished oxidative stress via p22phox, concluding that 'the protective effect of iron chelation in UUO-induced renal interstitial fibrosis involves the inhibition of oxidative stress, inflammation, and pro-fibrotic signaling.' The Results section 'Effect of Reduced Iron Content on the TGF-β-Smad Signaling Pathway' reports DFO reducing UUO-induced TGF-β1 expression (to 77%) and phospho-Smad3 (to 76%), and the Discussion's closing sentence attributes the prevention to inhibiting oxidative stress and TGF-β1-Smad3 activation. The citing sentence's hedge ('may') is weaker than the source's own conclusion, so it is fully supported. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype [57].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.1. Cancer
What the sources say
- Supportedcites [57] Pinnix Z. K. Miller L. D. Wang W. Ferroportin and iron regulation in breast cancer progression and prognosis Science Translational Medicine 2010 2 43 43ra56 10.1126/scisignal.3001127 2-s2.0-77955607931 PMC3734848 20686179 source
The Results section 'Ferroportin reduction in breast cancer cells is associated with an increase in labile iron' states that breast cancer cells, expressing low ferroportin, had significantly higher labile (metabolically available/free) iron than normal breast epithelial cells (Fig. 1F). The Discussion ties that same alteration to aggressive behavior: the ferroportin reduction occurred 'particularly in the more aggressive and invasive areas of the cancer,' was 'sufficient to alter the LIP ... and to affect growth of tumor xenografts,' and the abstract links lowest ferroportin with highest anaplasia. The paper's own mechanistic model therefore is that elevated cellular free iron accompanies a more aggressive breast cancer phenotype; note the association with grade/outcome was measured on ferroportin, with the LIP measured in cell lines, and the authors hedge the causal role ('may play a previously unappreciated role'). (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
39 more claims · 6 with their cited sources checked
Create a free account to see all 79 claims and to verify the 68 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Lehmann et al., 2015
Experimental — accuracy not yet measured
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 1×
“Low levels of ROS act as second messengers in many important signaling pathways, while prolonged exposure to higher levels can exceed cellular antioxidant defenses and damageDNA, lipids, and proteins [21, 23].”
BackgroundHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 2×
“Hepcidin is normally upregulated by excess iron stores [17].”
BackgroundWeiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“To mitigate iron losses from the body from shedding of epithelial cells and menstruation, the body must absorb an equivalent amount of iron from the gut, maintaining an overall iron balance.”
BackgroundAndrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130
Progress in Clinical and Biological Research
Smyth, J. F. (1979) · Journal of Clinical Pathology · doi:10.1136/jcp.32.7.742-d · Cited by 1,543
Iron Metabolism in Pathogenic Bacteria
Ratledge, C., & Dover, L. G. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.881 · Cited by 1,539 · cited 1×
“Both pathogenic bacteria [38] and fungi [39] can produce iron chelating siderophores as one strategy for obtaining host iron that is essential to their growth and pathogenesis [37, 39].”
BackgroundHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Dysmetabolic Hyperferritinemia: All Iron Overload Is Not Hemochromatosis
Makker, J., Hanif, A., Bajantri, B., & Chilimuri, S. (2015) · Case Reports in Gastroenterology · doi:10.1159/000373883 · Cited by 1,351
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · cited 7×
“It limits the cellular iron efflux by binding to FPN and facilitates its internalization and ultimate degradation [14].”
BackgroundInfluentialChoi, A. M., & Alam, J. (1996) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.15.1.8679227 · Cited by 1,126
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 1×
“To mitigate iron losses from the body from shedding of epithelial cells and menstruation, the body must absorb an equivalent amount of iron from the gut, maintaining an overall iron balance.”
BackgroundSazawal, S., Black, R. E., Ramsan, M., Chwaya, H. M., Stoltzfus, R. J., Dutta, A., Dhingra, U., Kabole, I., Deb, S., Othman, M. K., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67962-2 · Cited by 981
RNAi-Mediated Chromatin Silencing in Fission Yeast
White, S. A., & Allshire, R. C. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75157-1_8 · Cited by 971
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Antioxidant and Anti-Inflammatory Activities of Essential Oils: A Short Review
Miguel, M. G. (2010) · Molecules · doi:10.3390/molecules15129252 · Cited by 933
Definition, Classification and Diagnosis of Diabetes Mellitus
Kerner, W., & Brückel, J. (2014) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0034-1366278 · Cited by 863 · cited 1×
“Diabetes mellitus is characterized by an impaired glucose metabolism with the main symptom of hyperglycemia, caused either by impaired insulin secretion or impaired insulin action or both [77].”
BackgroundIron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site.
Graf, E., Mahoney, J. R., Bryant, R. G., & Eaton, J. W. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43139-5 · Cited by 855
Chemistry and biology of eukaryotic iron metabolism
Aisen, P. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00063-2 · Cited by 804
The Battle for Iron between Bacterial Pathogens and Their Vertebrate Hosts
Skaar, E. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000949 · Cited by 796 · cited 1×
“Iron withholding andmicrobial acquisition are key aspects of the host parasite battle during the pathogenesis of infection [40, 41].”
BackgroundOxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences
Tezel, G. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.07.003 · Cited by 723 · cited 1×
“Elevated intraocular pressure, the main risk factor for glaucoma, triggers the initiation and progression of oxidative stress-induced cell damage [81].”
BackgroundRedox Redux: Revisiting PTPs and the Control of Cell Signaling
Tonks, N. K. (2005) · Cell · doi:10.1016/j.cell.2005.05.016 · Cited by 702 · cited 1×
“Low levels of ROS act as second messengers in many important signaling pathways, while prolonged exposure to higher levels can exceed cellular antioxidant defenses and damageDNA, lipids, and proteins [21, 23].”
BackgroundSutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., & Greaves, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4515 · Cited by 685 · cited 2×
“Thus, cancer cells have increased expression of transferrin receptor-1 and a higher rate of iron uptake from transferrin [55, 56], as well as decreased expression of iron exporters [57].”
BackgroundReactive nitrogen species in the chemical biology of inflammation
Dedon, P. C., & Tannenbaum, S. R. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.12.017 · Cited by 681 · cited 5×
“ROS and RNS generation can lead to significant tissue damage and is responsible for a variety of inflammatory disease processes [20–22].”
BackgroundInfluentialAndrews, N. C., & Schmidt, P. J. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.164337 · Cited by 642 · cited 1×
“Due to their role in iron recycling from erythrocytes, iron loading in macrophages is particularly significant [31].”
BackgroundOxidative damage and protection of the RPE
Cai, J., Nelson, K. C., Wu, M., Sternberg, P., & Jones, D. P. (2000) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(99)00009-9 · Cited by 628 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundThe Role of Hepcidin in Iron Metabolism
Nemeth, E., & Ganz, T. (2009) · Acta Haematologica · doi:10.1159/000243791 · Cited by 607 · cited 1×
“Iron absorption by enterocytes and the recycled iron efflux from macrophages are controlled by hepcidin, a key iron regulatory hormone produced by hepatocytes [12, 13].”
BackgroundThe Concept of Normal Weight Obesity
Oliveros, E., Somers, V. K., Sochor, O., Goel, K., & Lopez-Jimenez, F. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.10.003 · Cited by 601 · cited 1×
“Obesity is characterized by an increase in the number and/or the size of the fat cells [78].”
BackgroundROS, stress‐activated kinases and stress signaling in cancer
Benhar, M., Engelberg, D., & Levitzki, A. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf094 · Cited by 600
Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid
Davies, K. J. A., Sevanian, A., Muakkassah-Kelly, S. F., & Hochstein, P. (1986) · Biochemical Journal · doi:10.1042/bj2350747 · Cited by 558
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554 · cited 2×
“…Egypt 7 Chelation Partners Inc., 1411 Oxford St., Halifax, NS, Canada B3H 3Z1 Correspondence should be addressed to C. Lehmann; chlehmann@dal.ca Received 20 June 2014; Revised 1 September 2014; Accepted 1 September 2014 Academic Editor: Yung-Hsiang Chen Copyright © 2015 C. Lehmann et al. This…”
BackgroundApoptotic cell: linkage of inflammation and wound healing
Wu, Y.-S., & Chen, S.-N. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00001 · Cited by 500
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498 · cited 1×
“Hypoferremia in SIRS is observed in humans [83] and animals [84, 85].”
BackgroundIron Homeostasis and the Inflammatory Response
Wessling-Resnick, M. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104804 · Cited by 480 · cited 2×
“Review Article The Utility of Iron Chelators in the Management of Inflammatory Disorders C. Lehmann,1,2,3 S. Islam,1,3,4 S. Jarosch,1 J. Zhou,1,2 D. Hoskin,2,5 A. Greenshields,5 N. Al-Banna,1 N. Sharawy,1,6 A. Sczcesniak,3 M. Kelly,1,3 K. Wafa,1 W. Cheliak,7 and B. Holbein7 1 Department of Anesthesia, Pain Management…”
Seril, D. N. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.353 · Cited by 467 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundThe adverse effect of iron repletion on the course of certain infections.
Murray, M. J., Murray, A. B., Murray, M. B., & Murray, C. J. (1978) · BMJ · doi:10.1136/bmj.2.6145.1113 · Cited by 453 · cited 1×
“For tuberculosis, it has been demonstrated that parenteral or oral iron increase mycobacterial growth [128] and that morbidity andmortality increase in patients receiving iron supplementation [129].”
BackgroundThe role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Pinnix, Z. K., Miller, L. D., Wang, W., D’Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001127 · Cited by 448 · cited 2×
“Interestingly, higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype [57].”
BackgroundBrain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445
IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA
Pippard, M. J., Warner, G. T., Callender, S. T., & Weatherall, D. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92175-5 · Cited by 419 · cited 1×
“, thalassemia intermedia) receive few or no transfusions but still become severely iron-overloaded [103].”
BackgroundIron, hemochromatosis, and hepatocellular carcinoma
Kowdley, K. V. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.019 · Cited by 391 · cited 2×
“The iron-catalyzed production of ROS and subsequent damage to DNA can result in the loss of tumor suppressors and activation of oncogenes [51, 52].”
BackgroundTLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens
Peyssonnaux, C., Zinkernagel, A. S., Datta, V., Lauth, X., Johnson, R. S., & Nizet, V. (2006) · Blood · doi:10.1182/blood-2005-06-2259 · Cited by 379 · cited 1×
“Hepcidin is also produced by macrophages and neutrophils during the innate immune response through a Toll-like receptor 4-dependent pathway [19].”
BackgroundUrrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N. P., Arredondo, M., González‐Billault, C., & Núñez, M. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12244 · Cited by 364 · cited 1×
“To mitigate iron losses from the body from shedding of epithelial cells and menstruation, the body must absorb an equivalent amount of iron from the gut, maintaining an overall iron balance.”
BackgroundIron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361 · cited 1×
“Colitis is another example for chronic inflammation, leading to anemia of inflammation as a consequence of low serum iron and low iron-binding capacity [92].”
BackgroundSerum Ferritin as a Component of the Insulin Resistance Syndrome
Fernández-Real, J.-M., Ricart-Engel, W., Arroyo, E., Balançá, R., Casamitjana-Abella, R., Cabrero, D., Fernández-Castañer, M., & Soler, J. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.62 · Cited by 328 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundIron at the interface of immunity and infection
Nairz, M., Haschka, D., Demetz, E., & Weiss, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00152 · Cited by 325 · cited 1×
“Iron withdrawal is part of the natural innate immune response in inflammation [3].”
BackgroundIron metabolism in the anemia of chronic disease
Weiss, G. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.006 · Cited by 322 · cited 1×
“Nonheme iron crosses the apical brush border membrane of enterocytes after conversion into ferrous iron by duodenal cytochrome B [7].”
BackgroundShared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans
Caza, M., & Kronstad, J. W. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00080 · Cited by 306 · cited 1×
“Iron withholding andmicrobial acquisition are key aspects of the host parasite battle during the pathogenesis of infection [40, 41].”
BackgroundRenal interstitial fibrosis: mechanisms and evaluation
Farris, A. B., & Colvin, R. B. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283521cfa · Cited by 298 · cited 1×
“Renal interstitial fibrosis is characterized by the accumulation of collagen and related molecules in the interstitium, involving cells like tubular epithelial cells, fibroblasts, fibrocytes, myofibroblasts, monocyte/macrophages, andmast cells [79], and can be caused inter alia by inflammatory processes [80].”
BackgroundAssociation Between Body Iron Stores and the Risk of Acute Myocardial Infarction in Men
Tuomainen, T.-P., Punnonen, K., Nyyssönen, K., & Salonen, J. T. (1998) · Circulation · doi:10.1161/01.cir.97.15.1461 · Cited by 286 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundRedox signaling and cancer: The role of “labile” iron
Galaris, D., Skiada, V., & Barbouti, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.038 · Cited by 284 · cited 1×
“The iron-catalyzed production of ROS and subsequent damage to DNA can result in the loss of tumor suppressors and activation of oncogenes [51, 52].”
BackgroundEffects of iron and desferrioxamine on infections with Yersinia enterocolitica
Robins-Browne, R. M., & Prpic, J. K. (1985) · Infection and Immunity · doi:10.1128/iai.47.3.774-779.1985 · Cited by 268 · cited 1×
“While desferrioxamine reduced experimental LPSinduced inflammation in mice, its use and that of other microbial chelators need to be carefully considered given that these agents could potentially promote infection owing to their microbial origin, for example, as has been shown for desferrioxamine with Yersinia enteroc…”
BackgroundAcquisition, Transport, and Storage of Iron by Pathogenic Fungi
Howard, D. H. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.3.394 · Cited by 260 · cited 1×
“Both pathogenic bacteria [38] and fungi [39] can produce iron chelating siderophores as one strategy for obtaining host iron that is essential to their growth and pathogenesis [37, 39].”
BackgroundWaldvogel-Abramowski, S., Waeber, G., Gassner, C., Buser, A., Frey, B. M., Favrat, B., & Tissot, J.-D. (2014) · Transfusion Medicine and Hemotherapy · doi:10.1159/000362888 · Cited by 260
Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease.
Brewer, G. J. (2007) · PubMed · Cited by 245
Fuqua, B. K., Vulpe, C. D., & Anderson, G. J. (2012) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2012.03.015 · Cited by 241 · cited 3×
“Absorption declines to around 1mg/day in men and 2mg/day in women when growth declines [5].”
BackgroundKochan, I. (1973) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-65502-9_1 · Cited by 237 · cited 1×
“For tuberculosis, it has been demonstrated that parenteral or oral iron increase mycobacterial growth [128] and that morbidity andmortality increase in patients receiving iron supplementation [129].”
BackgroundRole of iron in postischemic renal injury in the rat
Paller, M. S., Hedlund, B. E., Sikora, J. J., Faassen, A., & Waterfield, R. (1988) · Kidney International · doi:10.1038/ki.1988.205 · Cited by 222 · cited 1×
“In the postischemic renal injury model in rats, acute iron loading exacerbated postischemic lipid peroxidation and renal injury, while reducing iron level by DFO suppressed lipid peroxidation and improved renal function [90].”
BackgroundFriedreich ataxia: the oxidative stress paradox
Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.-C., Koenig, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi042 · Cited by 219
Effect of hepcidin on intestinal iron absorption in mice
Laftah, A. H., Ramesh, B., Simpson, R. J., Solanky, N., Bahram, S., Schümann, K., Debnam, E. S., & Srai, S. K. S. (2004) · Blood · doi:10.1182/blood-2003-03-0953 · Cited by 217
The regulation of iron transport
Frazer, D. M., & Anderson, G. J. (2014) · BioFactors · doi:10.1002/biof.1148 · Cited by 216 · cited 1×
“Ferroxidase activity of ceruloplasmin or hephaestin is required to load iron safely onto transferrin [9].”
BackgroundWhat Is Responsible for the Initiating Chemistry of Iron-Mediated Lipid Peroxidation: An Update
Cheng, Z., & Li, Y. (2007) · Chemical Reviews · doi:10.1021/cr040077w · Cited by 211
Scott, M. D., van den Berg, J. J., Repka, T., Rouyer-Fessard, P., Hebbel, R. P., Beuzard, Y., & Lubin, B. H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116380 · Cited by 204 · cited 1×
“They described three potential mechanisms: (i) the excess α-chains in β-thalassemic erythrocytes and erythroblasts being unstable and prone to denaturation and oxidation, (ii) peroxidation of tissues that leak malondialdehyde into the blood, and (iii) depleted antioxidant capacity lowering defense against oxidants [10…”
BackgroundDisorders of iron metabolism. Part 1: molecular basis of iron homoeostasis
Muñoz, M., García-Erce, J. A., & Remacha, Á. F. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.079046 · Cited by 200 · cited 1×
“, trauma and surgery) the two major mechanisms leading to anemia are blood loss and blunted erythropoiesis due to decreased iron availability [93, 94].”
BackgroundClinical presentation of hemochromatosis: A changing scene
Adams, P. C., Kertesz, A. E., & Valberg, L. S. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80084-y · Cited by 198 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundHepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia
Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O. E., & Ganz, T. (2005) · Blood · doi:10.1182/blood-2004-08-3375 · Cited by 196 · cited 1×
“The end result is that iron cannot be released into the plasma and remains trapped inside the macrophages and hepatocytes, resulting in an increase in iron stores reflected in high levels of serum ferritin [29].”
BackgroundAssociation of Pulmonary Tuberculosis with Increased Dietary Iron
Gangaidzo, I. T., Moyo, V. M., Mvundura, E., Aggrey, G., Murphree, N. L., Khumalo, H., Saungweme, T., Kasvosve, I., Gomo, Z. A. R., Rouault, T., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/323203 · Cited by 191 · cited 1×
“In fact, dietary iron is associated with occurrence and death from tuberculosis [130].”
BackgroundHypoxia-regulated target genes implicated in tumor metastasis
Tsai, Y.-P., & Wu, K.-J. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-102 · Cited by 190
Host-Pathogen Interactions: The Role of Iron1,
Doherty, C. P. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.5.1341 · Cited by 186 · cited 1×
“Iron overload associated with hereditary hemochromatosis has been reported to confer susceptibility to infectious pathogens, such as Yersinia enterocolitica and Vibrio vulnificus [101].”
BackgroundMechanisms of hepatic ischemia-reperfusion injury and protective effects of nitric oxide
Guan, L.-Y. (2014) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v6.i7.122 · Cited by 186
The uptake of iron and transferrin by the human malignant melanoma cell
Richardson, D. R., & Baker, E. (1990) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(90)90018-9 · Cited by 179 · cited 1×
“Thus, cancer cells have increased expression of transferrin receptor-1 and a higher rate of iron uptake from transferrin [55, 56], as well as decreased expression of iron exporters [57].”
BackgroundIron in arterial plaque: A modifiable risk factor for atherosclerosis
Sullivan, J. L. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.06.005 · Cited by 176 · cited 1×
“This assumption is based on traditional medical practices rather than on rigorous clinical trials [133].”
MethodIron and Immunity: Immunological Consequences of Iron Deficiency and Overload
Cherayil, B. J. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0095-9 · Cited by 170 · cited 3×
“In addition, iron regulates the activity of the transcription factors NF-𝜅B and HIF-1𝛼 [58], which promote the expression of genes involved in the survival andmetastasis of cancer cells [59, 60].”
BackgroundMutti, A., Corradi, M., Goldoni, M., Vettori, M. V., Bernard, A., & Apostoli, P. (2006) · Chest · doi:10.1378/chest.129.5.1288 · Cited by 157 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundIron metabolism and erythropoiesis after surgery
van Iperen, C. E., Kraaijenhagen, R. J., Biesma, D. H., Beguin, Y., Marx, J. J. M., & van de Wiel, A. (1998) · Journal of British Surgery · doi:10.1046/j.1365-2168.1998.00571.x · Cited by 153
Wang, J., Song, N., Jiang, H., Wang, J., & Xie, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.021 · Cited by 150 · cited 1×
“To mitigate iron losses from the body from shedding of epithelial cells and menstruation, the body must absorb an equivalent amount of iron from the gut, maintaining an overall iron balance.”
BackgroundKalinowski, D. S., & Richardson, D. R. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700039c · Cited by 145 · cited 2×
“Kalinowski and Richardson have recently reviewed synthetic chelators based on various chelating chemical groupings such as catechol, hydroxamate, and hydroxypyridinone, concluding that structures providing hexadentate hydroxypyridinone functionality (an example being deferiprone) have particular promise as bacteriosta…”
BackgroundKasarskis, E. J., Tandon, L., Lovell, M. A., & Ehmann, W. D. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00037-3 · Cited by 145
Reactive oxygen species in the neuropathogenesis of hypertension
Peterson, J. R., Sharma, R. V., & Davisson, R. L. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0056-1 · Cited by 139 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundAntibacterial Activities of Iron Chelators against Common Nosocomial Pathogens
Thompson, M. G., Corey, B. W., Si, Y., Craft, D. W., & Zurawski, D. V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01197-12 · Cited by 135 · cited 1×
“However, the hydroxamate desferal and the hydroxypyridinone deferiprone have been shown to be accessible by various micoorganisms thereby restricting their potential use as microbial control agents [50].”
BackgroundMcKie, A. T., & Simpson, R. J. (2012) · Iron Physiology and Pathophysiology in Humans · doi:10.1007/978-1-60327-485-2_6 · Cited by 132
Panieri, E., Gogvadze, V., Norberg, E., Venkatesh, R., Orrenius, S., & Zhivotovsky, B. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.12.024 · Cited by 132 · cited 2×
“When the iron demand of the body is high, iron crosses the basolateral membrane via the iron export protein ferroportin1 (FPN) and enters the circulation, ultimately binding to transferrin.”
BackgroundThe role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies
Schwartz, S. A., Hernandez, A., & Mark Evers, B. (1999) · Surgical Oncology · doi:10.1016/s0960-7404(00)00012-8 · Cited by 132
Klouwenberg, P. M. C. K., Ong, D. S. Y., Bonten, M. J. M., & Cremer, O. L. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2549-5 · Cited by 125 · cited 1×
“Systemic inflammatory response syndrome (SIRS) is characterized by specific physiological alterations, including temperature, white blood cell count, heart rate, and respiratory rate, caused by a broad spectrum of noninfectious and infectious triggers [82].”
BackgroundIron activates NF-κB in Kupffer cells
She, H., Xiong, S., Lin, M., Zandi, E., Giulivi, C., & Tsukamoto, H. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00108.2002 · Cited by 121
Low-grade inflammation and the metabolic syndrome in children and adolescents
Wärnberǵ, J., & Marcos, A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f4096b · Cited by 118 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundIron in the synovial membrane in rheumatoid arthritis and other joint diseases.
Muirden, K. D., & Senator, G. B. (1968) · Annals of the Rheumatic Diseases · doi:10.1136/ard.27.1.38 · Cited by 113 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundTajima, S., Ikeda, Y., Sawada, K., Yamano, N., Horinouchi, Y., Kihira, Y., Ishizawa, K., Izawa-Ishizawa, Y., Kawazoe, K., Tomita, S., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00033.2011 · Cited by 112 · cited 2×
“Diabetes and Obesity Role of iron in adiposity using diabetic and obese mice model (KKAy) DFO treatment DFO diminished fat iron and serum ferritin levels, reduced fat weight and adipocyte size, and reduced macrophage infiltration, superoxide production, NADPH oxidase activity, and mRNA of inflammatory cytokines [65]”
BackgroundClinical presentation of hemochromatosis: A changing scene
Adams, P. C., Kertesz, A. E., & Valberg, L. S. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90604-v · Cited by 111
The role of labile iron pool in cardiovascular diseases.
Kruszewski, M. (2004) · Acta Biochimica Polonica · doi:10.18388/abp.2004_3585 · Cited by 107 · cited 1×
“ONOO andH 2 O 2 produced in the reperfusion phase are known to release iron ions from intracellular iron-sulphur proteins thus increasing intracellular labile iron pool, which in turn promotes by the above-outlined reactions the production of further reactive species [89].”
BackgroundIron-controlled infection with Neisseria meningitidis in mice
Holbein, B. E. (1980) · Infection and Immunity · doi:10.1128/iai.29.3.886-891.1980 · Cited by 103 · cited 1×
“Hypoferremia in SIRS is observed in humans [83] and animals [84, 85].”
BackgroundSelf-citationIron storage disease: Facts, fiction and progress
Beutler, E. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.03.009 · Cited by 101 · cited 2×
“Most forms of hemochromatosis result from dysregulation of hepcidin or defects of hepcidin or ferroportin themselves [100].”
BackgroundIkeda, Y., Ozono, I., Tajima, S., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Miyamoto, L., Ishizawa, K., Tsuchiya, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089355 · Cited by 98 · cited 2×
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
BackgroundIron-Sensing Proteins that Regulate Hepcidin and Enteric Iron Absorption
Knutson, M. D. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104801 · Cited by 96 · cited 1×
“Iron absorption by enterocytes and the recycled iron efflux from macrophages are controlled by hepcidin, a key iron regulatory hormone produced by hepatocytes [12, 13].”
BackgroundIntestinal Iron Absorption: Regulation by Dietary & Systemic Factors
Sharp, P. A. (2010) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000029 · Cited by 95 · cited 1×
“In total, the human body contains approximately 3 to 4 g of iron in the form of both heme and nonheme iron [10].”
BackgroundThe iron hypothesis of atherosclerosis and its clinical impact
Yuan, X., & Li, W. (2003) · Annals of Medicine · doi:10.1080/07853890310016342 · Cited by 93 · cited 1×
“The “iron hypothesis” of the benefits of some iron depletion due to menstruation was devised to account for the lowering of heart-disease risk in young women that disappears in those who are postmenopausal [131, 132].”
BackgroundWalter, P. B., Macklin, E. A., Porter, J., Evans, P., Kwiatkowski, J. L., Neufeld, E. J., Coates, T., Giardina, P. J., Vichinsky, E., Olivieri, N., et al. (2008) · Haematologica · doi:10.3324/haematol.11755 · Cited by 87
Comparison of the main siderophores produced by some species of Streptomyces
Imbert, M. X. E. N., B�chet, M., & Blondeau, R. (1995) · Current Microbiology · doi:10.1007/bf00294289 · Cited by 84 · cited 1×
“Both pathogenic bacteria [38] and fungi [39] can produce iron chelating siderophores as one strategy for obtaining host iron that is essential to their growth and pathogenesis [37, 39].”
BackgroundRitter, C., Reinke, A., Andrades, M., Martins, M. R., Rocha, J., Menna-Barreto, S., Quevedo, J., Moreira, J. C. F., & Dal-Pizzol, F. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000142699.54266.d9 · Cited by 82
Sullivan, J. L. (2004) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2004.10.006 · Cited by 82 · cited 1×
“Because of the deeply rooted assumption that stored iron is safe, appropriate trials to rule out the potential hazards of iron stores have not been undertaken [134].”
BackgroundIron-dependent activation of NF-κB in Kupffer cells: a priming mechanism for alcoholic liver disease
Xiong, S., She, H., Sung, C. K., & Tsukamoto, H. (2003) · Alcohol · doi:10.1016/s0741-8329(03)00100-9 · Cited by 82 · cited 1×
“Tissuemacrophages phagocytize senescent red blood cells to recover, turnover, and recycle iron.”
BackgroundWeinberg, E. D. (2010) · Metallomics · doi:10.1039/c0mt00023j · Cited by 81
Serum ferritin as a serologic marker of activity in systemic lupus erythematosus
Lim, M.-K., Lee, C.-K., Ju, Y.-M., Cho, Y. S., Lee, M.-S., Yoo, B., & Moon, H. (2001) · Rheumatology International · doi:10.1007/s002960000083 · Cited by 80
The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease
Mercadel, L., Metzger, M., Haymann, J., Thervet, É., Boffa, J., Flamant, M., Vrtovsnik, F., Houillier, P., Froissart, M., Stengel, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099781 · Cited by 74 · cited 1×
“Poor gut iron absorption can be predicted by elevated hepcidin level [15].”
BackgroundThe Interplay between Inflammation and Fibrosis in Kidney Transplantation
Torres, I. B., Moreso, F., Sarró, E., Meseguer, A., & Serón, D. (2014) · BioMed Research International · doi:10.1155/2014/750602 · Cited by 73 · cited 1×
“Renal interstitial fibrosis is characterized by the accumulation of collagen and related molecules in the interstitium, involving cells like tubular epithelial cells, fibroblasts, fibrocytes, myofibroblasts, monocyte/macrophages, andmast cells [79], and can be caused inter alia by inflammatory processes [80].”
BackgroundIbuprofen prevents oxidant lung injury and in vitro lipid peroxidation by chelating iron.
Kennedy, T. P., Rao, N. V., Noah, W., Michael, J. R., Jafri, M. H., Gurtner, G. H., & Hoidal, J. R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114876 · Cited by 72 · cited 1×
“As to synthetic agents with antiinflammatory activity, ibuprofen, a widely used synthetic anti-inflammatory agent, has been shown to chelate iron in a stable formwithout a free Fenton-reactive coordination site and to protect from lipid peroxidation in vitro and phosgeneinduced septic lung injury in rabbits [48].”
BackgroundHepcidin and Ferroportin: The New Players in Iron Metabolism
De Domenico, I., Ward, D., & Kaplan, J. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1286058 · Cited by 71
Antimalarial Activity of Selected Aromatic Chelators
Scheibel, L. W., & Adler, A. (1981) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13895-9 · Cited by 69
Kruzel, M. L., Actor, J. K., Radak, Z., Bacsi, A., Saavedra-Molina, A., & Boldogh, I. (2010) · Innate Immunity · doi:10.1177/1753425909105317 · Cited by 69 · cited 1×
“In an endotoxemic mouse model, lactoferrin, a nonheme iron-binding glycoprotein, decreased LPS-induced oxidative burst and reactive oxygen species in cultured cells and attenuated mitochondrial dysfunction in liver of endotoxemic mice [86].”
BackgroundPreventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.
Minaiyan, M., Mostaghel, E. A., & Mahzouni, P. (2012) · PubMed Central · Cited by 62
Therapeutic approaches to drug targets in atherosclerosis
Jamkhande, P. G., Chandak, P. G., Dhawale, S. C., Barde, S. R., Tidke, P. S., & Sakhare, R. S. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.04.005 · Cited by 59
Ishizaka, N., Saito, K., Mori, I., Matsuzaki, G., Ohno, M., & Nagai, R. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000181763.57495.2b · Cited by 55
Zinc supplementation decreases the development of atherosclerosis in rabbits
Ren, M., Rajendran, R., Ning, P., Huat, B. T. K., Nam, O. C., Watt, F., Jenner, A. M., & Halliwell, B. B. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.03.017 · Cited by 52 · cited 2×
“Increased levels of iron and oxidized lipids are both found in high-cholesterol diet-fed rabbits associated with atherosclerotic lesions [62].”
BackgroundVlahakos, D., Arkadopoulos, N., Kostopanagiotou, G., Siasiakou, S., Kaklamanis, L., Degiannis, D., Demonakou, M., & Smyrniotis, V. (2012) · Artificial Organs · doi:10.1111/j.1525-1594.2011.01385.x · Cited by 51
The Anemia Associated With Chronic Infection
Cartwright, G. E., Lauritsen, M. A., Humphreys, S., Jones, P. J., Merrill, I. M., & Wintrobe, M. M. (1946) · Science · doi:10.1126/science.103.2664.72 · Cited by 51
Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Yuan, X.-M., & Li, W. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785747634 · Cited by 51 · cited 1×
“It has been suggested that the development of atherosclerosis is associated with the amount of iron stored in the body and iron may contribute to the pathogenesis of atherosclerosis by acting as a regulator of vascular oxidative stress and inflammatory immune responses in atherosclerosis [75].”
BackgroundDomellöf, M., Þórsdóttir, I., & Thorstensen, K. (2013) · Food & Nutrition Research · doi:10.3402/fnr.v57i0.21667 · Cited by 47 · cited 1×
“Iron requirements are high during infancy, childhood, and pregnancy [6].”
BackgroundSrichairatanakool, S., Thephinlap, C., Phisalaphong, C., Porter, J., & Fucharoen, S. (2007) · Medicinal Chemistry · doi:10.2174/157340607781745447 · Cited by 46
Atkinson, S. H., Rockett, K. A., Morgan, G., Bejon, P. A., Sirugo, G., O'Connell, M. A., Hanchard, N., Kwiatkowski, D. P., & Prentice, A. M. (2008) · Blood · doi:10.1182/blood-2008-06-162008 · Cited by 43
Therapeutic Potential of Iron Chelators in Cancer Therapy
Richardson, D. R. (2002) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0593-8_12 · Cited by 40 · cited 1×
“It follows that cancer cells are more sensitive to iron deprivation than normal cells and may therefore be susceptible to treatment with iron chelators [61].”
BackgroundPrevention and modulation of aminoglycoside ototoxicity (Review)
Willems, P., Fasano, M., Magri, V., et al. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.1.3 · Cited by 39
Premature Atherosclerosis in Children With β-Thalassemia Major
Gürsel, O., Kürekçi, A. E., Taşçılar, E., İleri, T., Altun, D., Tapan, S., Kurt, İ., Kocaoğlu, M., Aydın, A., Okutan, V., et al. (2012) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3182707f4d · Cited by 39
Holbein, B. E., & Mira de Orduña, R. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01956.x · Cited by 36 · cited 2×
“While desferrioxamine reduced experimental LPSinduced inflammation in mice, its use and that of other microbial chelators need to be carefully considered given that these agents could potentially promote infection owing to their microbial origin, for example, as has been shown for desferrioxamine with Yersinia enteroc…”
BackgroundSelf-citationWhat is a role of haeme oxygenase‐1 in psoriasis? Current concepts of pathogenesis
Wojas‐Pelc, A., & Marcinkiewicz, J. (2007) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2006.00505.x · Cited by 36 · cited 1×
“Iron accumulation and increased oxidative stress were also described in the pathogenesis of preeclampsia [2], diabetes [106], the metabolic syndrome [107], obesity [108], hypertension [109], cardiovascular diseases [110], heart failure [95], atherosclerosis [111], stroke [112], Alzheimer’s, Parkinson’s and other major…”
BackgroundInflammation and diminished iron status: mechanisms and functional outcomes
Gaffney-Stomberg, E., & McClung, J. P. (2012) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328357f63b · Cited by 33 · cited 2×
“However, in ACD or inflammation without infection, this mechanism can have detrimental consequences when iron remains sequestered in the macrophages and hepatocytes and is not available for erythropoiesis, resulting in anemia [97].”
BackgroundEfficacy of Curcuminoids in Alleviation of Iron Overload and Lipid Peroxidation in Thalassemic Mice
Thephinlap, C., Phisalaphong, C., Fucharoen, S., Porter, J., & Srichairatanakool, S. (2009) · Medicinal Chemistry · doi:10.2174/157340609789117912 · Cited by 32 · cited 1×
“For example, curcuminoids bind ferric iron in vitro and alleviate iron toxicity in thalassemic mice [45, 46].”
BackgroundDesferrioxamine attenuates minor lung injury following surgical acute liver failure
Kostopanagiotou, G. G., Kalimeris, K. A., Arkadopoulos, N. P., Pafiti, A., Panagopoulos, D., Smyrniotis, V., Vlahakos, D., Routsi, C., Lekka, M. E., & Nakos, G. (2009) · European Respiratory Journal · doi:10.1183/09031936.00123108 · Cited by 32 · cited 2×
“permeability, and prevented alveolar space collapse [72]”
MethodBeaumier, D. L., Caldwell, M. A., & Holbein, B. E. (1984) · Infection and Immunity · doi:10.1128/iai.46.2.489-494.1984 · Cited by 30
Self-citationWitmer, C. M. (2013) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.08.012 · Cited by 29 · cited 2×
“Ferrous sulfate is the most common oral iron supplement used [126].”
BackgroundLiu, P., Zhang, M., Shoeb, M., Hogan, D., Tang, L., Syed, M. F., Wang, C. Z., Campbell, G. A., & Ansari, N. H. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.01.039 · Cited by 28
Intracellular Redox Compartments: Mechanisms and Significances
Kietzmann, T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3001 · Cited by 28 · cited 8×
“It limits the cellular iron efflux by binding to FPN and facilitates its internalization and ultimate degradation [14].”
BackgroundInfluentialDzikaite, V., Holmström, P., Stål, P., Eckes, K., Hagen, K., Eggertsen, G., Gåfvels, M., Melefors, Ö., & Hultcrantz, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.028 · Cited by 26
Glaucoma Prevalence and the Intake of Iron and Calcium in a Population-based Study
Wang, S. Y., Singh, K., & Lin, S. C. (2013) · Current Eye Research · doi:10.3109/02713683.2013.803124 · Cited by 25 · cited 2×
“observed a correlation of iron intake and the odds of glaucoma in humans [68].”
BackgroundMasuda, Y., Ichii, H., & Vaziri, N. D. (2013) · Europe PMC (PubMed Central) · Cited by 25
Iron Chelation and Vascular Function: In Search of the Mechanisms
Ferrara, D. E., & Taylor, W. R. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000189303.45609.1f · Cited by 21
Therapeutic role of natural agents in beta-thalassemia: A review
Kukreja, A., Wadhwa, N., & Tiwari, A. (2013) · Journal of Pharmacy Research · doi:10.1016/j.jopr.2013.10.002 · Cited by 19 · cited 1×
“[47] recently reviewed the iron chelating activity ofAfrican walnut and wheat grass extracts as to their potential for natural iron removal agents for iron overload associated with thalassemia, which is currently typically treated clinically with desferal.”
BackgroundSurgical Inflammation Induces Hepcidin Production after Abdominal Surgery
Park, K. H., Sawada, T., Kosuge, T., Kita, J., Shimoda, M., Tomosugi, N., & Kubota, K. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1473-8 · Cited by 18 · cited 1×
“Circulating hepcidin expression in vivo has also been correlated with acute phase proteins such as C-reactive protein, α-1-acid-glycoprotein, ferritin, and amyloid A [96, 97].”
BackgroundAnimal models of neonatal stroke and response to erythropoietin and cardiotrophin‐1
Sola, A., Peng, H., Rogido, M. R., & Wen, T. (2007) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2007.08.016 · Cited by 17
Effects of pentastarch-deferoxamine conjugate on lung injury after cardiopulmonary bypass.
Stamler, A., Wang, S. Y., Aguirre, D., et al. (1996) · PubMed · Cited by 17
Antimalarial Activity of Selected Aromatic Chelators
SCHEIBEL, L. W., & ADLER, A. (1980) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14414-3 · Cited by 14
Arkadopoulos, N., Vlahakos, D., Kostopanagiotou, G., Panagopoulos, D., Karvouni, E., Routsi, C., Kalimeris, K., Andreadou, I., Kouskouni, E., & Smyrniotis, V. (2008) · Liver Transplantation · doi:10.1002/lt.21505 · Cited by 13
Cazzola, M., & Finch, C. A. (1989) · PubMed · Cited by 9
Cited by
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Iron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
Kell, D. B., & Pretorius, E. (2018) · Biological Reviews · doi:10.1111/brv.12407 · Cited by 110
“…2015; Hansen, Moen & Mandrup-Poulsen, 2014; Jellen, Beard & Jones, 2009; Kell, 2009, 2010; Kell & Pretorius, 2014; Koskenkorva-Frank et al., 2013; Lehmann et al., 2015; Levi & Finazzi, 2014; Mollet et al., 2016; Muhoberac & Vidal, 2013; Muller & Leavitt, 2014; Nikonorov et al., 2015; Núñez et…”
Hezaveh, Z. S., Azarkeivan, A., Janani, L., Hosseini, S., & Shidfar, F. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.02.017 · Cited by 62
Chelators in Iron and Copper Toxicity
Lawson, M. K., Valko, M., Cronin, M., & Jomová, K. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0068-8 · Cited by 62
Metadata
- Authors
- Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., Wafa, K., Cheliak, W., & Holbein, B.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Lehmann, C.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 516740-516740
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4386698
- OpenAlex
- W1974910643
- Cited by
- 54
- References
- 145
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 5
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- iron chelators, iron regulation, inflammation, Fenton reaction, Haber-Weiss reaction, iron availability, oxidative stress, chronic inflammatory diseases, acute inflammatory diseases, cancer
- MeSH terms
- Animals, Fibrosis, Hemochromatosis, Humans, Inflammation, Iron, Iron Chelating Agents, Kidney, Neoplasms, Reactive Oxygen Species, Systemic Inflammatory Response Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.